^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EP-101 STEMVAC

    i
    Other names: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, EP-101 STEMVAC, STEMVAC
    Associations

    News

    Trials
    Company:
    EpiThany, University of Washington
    Drug class:
    Th1 cell stimulant
    Related drugs:
    Associations

    News

    Trials
    6d
    Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, University of Washington | Trial completion date: Feb 2027 --> Sep 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    EP-101 STEMVAC
    2ms
    A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Washington | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    ENG (Endoglin)
    |
    cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)
    4ms
    STEMVAC in Patients With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jul 2028 | Trial primary completion date: Dec 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    5ms
    A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    capecitabine • EP-101 STEMVAC
    6ms
    A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, University of Washington | N=40 --> 5
    Enrollment change
    |
    ENG (Endoglin)
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    6ms
    A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, University of Washington
    New P2 trial
    |
    capecitabine • EP-101 STEMVAC
    7ms
    A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Washington
    New P2 trial
    |
    ENG (Endoglin)
    |
    cisplatin • carboplatin • paclitaxel • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • daunorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • EP-101 STEMVAC • Leukine (sargramostim)
    8ms
    A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ENG (Endoglin)
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    9ms
    STEMVAC in Patients With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, University of Washington | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    11ms
    The potential of ARL4C and its-mediated genes in atherosclerosis and agent development. (PubMed, Front Pharmacol)
    Many agents, including ABCA1 agonists (CS-6253, IMM-H007, RG7273, and R3R-01), FLNA antagonist sumifilam, LRP6 inhibitor BI-905677 and agonist SZN-1326, and SOX2 inhibitor STEMVAC, were investigated in clinical trials. Thus, ARL4C and its regulated genes may be a potential target for drug development. Thus, we focus on the role of ARL4C and its-mediated genes in atherosclerosis and agent development, which provide insights for the identification, research, and drug development of novel targets.
    Review • Journal
    |
    SOX2 • SNAI2 (Snail Family Transcriptional Repressor 2) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • ALDH1A3 (Aldehyde Dehydrogenase 1 Family Member A3)
    |
    EP-101 STEMVAC
    almost2years
    STEMVAC in Patients With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, University of Washington | Trial completion date: Apr 2024 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma)
    |
    HER-2 negative • HER-2 expression • PGR expression
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    2years
    A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Washington | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Jan 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CD4 (CD4 Molecule)
    |
    EP-101 STEMVAC • Leukine (sargramostim)